Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 6/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | PARG | Q86W56 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3648904 | 0.96 | LMNA (0.48) | LMNAMAPTHTR7ALDH1A1PRKCA | |
| SCHEMBL20371571 | 0.83 | LMNA (0.46) | LMNAMAPTALDH1A1PARG | |
| SCHEMBL14487357 | 0.80 | APEX1 (0.56) | LMNAMAPTGAAALDH1A1 | |
| SCHEMBL15730254 | 0.79 | LMNA (0.49) | LMNAMAPTUSP2NPSR1GAA | |
| SCHEMBL1186445 | 0.78 | HTR7 (0.58) | HTR7 | |
| SCHEMBL8129587 | 0.74 | LMNA (0.54) | LMNAMAPTALDH1A1 | |
| SCHEMBL11811721 | 0.74 | APEX1 (0.50) | LMNAGAAALDH1A1PRKCAGSK3B | |
| SCHEMBL15723841 | 0.72 | LMNA (0.46) | LMNAMAPT | |
| SCHEMBL4750197 | 0.72 | LMNA (0.41) | LMNAMAPTHTR7PARG | |
| Hydrochloric Acid SCHEMBL4290934 | 0.71 | PARP1 (0.35) | LMNAMAPTHTR7GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120220604-A1 | PIPERAZINYL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2012-08-30 | — | — | US | disclosed |
| WO-2011032903-A1 | PIPERAZINYL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220604-A1 | PIPERAZINYL-ALKYL-BENZOIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | LMNA 4383/4885MAPT 704/4885HTR7 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.